Unicycive Q1 2026 net loss $12.8M; OLC PDUFA target June 29, 2026

Unicycive Therapeutics, Inc.

2026-Q1 EPS reported -$0.54

Net loss of $12.8M ($0.54 per share basic/diluted) vs net income of $0.5M in Q1 2025.
Cash, cash equivalents & marketable securities $57.1M as of May 11, 2026; funds operations into 2027.
FDA PDUFA target action date for oxylanthanum carbonate NDA resubmission is June 29, 2026.
R&D expenses down to $1.6M (from $2.2M); G&A up to $6.8M (from $5.8M) year-over-year.
Commercial readiness activities ongoing for potential OLC launch after PDUFA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $(12.8) million loss, EPS $(0.54) per share of common stock.

Period: the first quarter ended March 31, 2026
Net income: $(12.8) million loss
EPS: $(0.54) per share of common stock
Result: reported results

Exact text from the filing

Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-054736

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.